Watch this CME-certified on-demand Webcast of a CCO live symposium from ASH 2019 to gain insights from the experts on best practices for the individualized care of patients with myeloproliferative neoplasms.
Outcomes are poor for patients with myelofibrosis who discontinue ruxolitinib due to loss of response or intolerance. In this commentary, I offer my thoughts on the best treatment options for these patients.
In this commentary, Raajit K. Rampal, MD, PhD, highlights key MPN studies that will be presented at the upcoming 2019 ASH annual meeting in Orlando.
Read expert answers to key questions from the audience at a recent symposium on optimal management of patients with myeloproliferative neoplasms.
Download this slideset for expert perspectives on current best practices on diagnosis, driver mutations, and risk stratification for patients with MPNs.
Download this slideset for expert perspectives on current best practices on managing patients with myelofibrosis.
Download this slideset for expert perspectives on emerging therapies and optimal management of patients with myelofibrosis that is intolerant/resistant to ruxolitinib.
Download this slideset for expert perspectives on best practice for managing patients with PV and ET.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.